The RECIST( Response Evaluation Criteria In Solid Tumors ) which measures tumor responses by imaging techniques including X-rays, CT scans and MRIs has been of less value whereas clinical benefit including Progression Free Survival remains more relevant when assessing efficacy of MKIs in metastatic Renal Cancer. The addition of Bevacizumab to Interferon alfa 2a was however not only associated with a significant improvement in progression free survival (10.4 months vs 5.5 months, HR =0.63, P<0.0001) but also overall response rate (31% vs 12%, P<0.0001) compared to Interferon plus placebo. This may be relevant if preoperative treatment for renal cancer is a consideration and this response rate efficacy parameter may also benefit patients who have symptomatic unresectable locally advanced Renal Cancer.
Other Pages – Bottom Ad
Advertisement
Subscribe
